The global infectious disease market is expected to grow at a CAGR of around 5.7% from 2020 to 2027 and expected to reach the market value of around US$ 24.5 Bn by 2027.
Infectious diseases are caused by microorganisms such as viruses, bacteria, fungi, or parasites and can be transmitted from person to person. Infectious diseases can be passed from person to person through contact with bodily fluids, aerosols (coughing and sneezing), or a vector, such as a mosquito. An infectious disease can affect anyone. People who have a compromised immune system (an immune system that does not function properly) are more vulnerable to certain types of infections. Infectious diseases are extremely common all over the world. Certain infectious diseases are more common than others. According to a Cleveland Clinic report, one out of every five people in the United States is infected with influenza (flu) virus each year.
Rising prevalence of infectious diseases bolster the growth of global infectious disease market
According to the Australian Institute of Health and Welfare, over 593,000 cases of notifiable diseases were reported to the NNDSS in 2019. In 2019, four infectious diseases accounted for 82% of these notifications to Australian health authorities. In addition, non-notifiable diseases accounted for 89 percent of the nearly 447,000 communicable disease hospitalizations in 2017-18. From 2000-01 to 2017-18, the hospitalization rate for non-notifiable communicable diseases reached a high of 15.3 per 1,000 people in 2016-17 (nearly 400,000 hospital separations). Lower respiratory tract infections (such as pneumonia and bronchitis) were the most commonly diagnosed infectious cause of hospitalization in 2017-18, accounting for nearly 145,000 hospitalizations. In 2018, communicable diseases were responsible for nearly 6,000 deaths in Australia. The vast majority (89%) of infections-related deaths were due to non-notifiable diseases, the most common of which were lower respiratory infections caused by various bacteria and viruses.
Rising demand for point-of-care testing supports the growth of the global infectious disease market
Point-of-care (POC) tests have the potential to improve the management of infectious diseases, especially in resource-limited settings where health care infrastructure is weak, and access to quality and timely medical care is a challenge. These tests offer rapid results, allowing for timely initiation of appropriate therapy, and/or facilitation of linkages to care and referral. According to the AdvaMed report, infectious diseases caused an economic burden of more than US$120 Bn in the United States alone in 2014. Point-of-care (POC) testing enables patient diagnosis to be made in the doctor's office, an ambulance, the patient's home, the field, or the hospital. The findings allow for more rapid treatment. During the recent Ebola outbreak, test manufacturers rushed to develop new point-of-care rapid diagnostic tests in order to avoid multi-day delays in diagnosing affected patients. The World Health Organization developed and approved four such tests between November 2014 and December 2015; the US Food and Drug Administration have authorized ten tests for emergency use. Researchers estimate that if these POC tests had been used during the epidemic, the scale of the epidemic could have been reduced by more than a third.
The global infectious disease market is segmented based on product, technology, application, and end-user. Based on product, the market is segregated as instruments, reagents, and services. By technology, the market is segmented as immunoassay, molecular diagnostics, microbiology, and others. By application, the market is segmented as MRSA, streptococcus, clostridium difficile, VRE, CRE, respiratory virus, candida, TB and drug-resistant TB, gastro-intestinal panel testing, chlamydia, gonorrhea, HPV, HIV, Hepatitis, Hepatitis B, COVID-19, and others. Based on end-users, the market is segmented as point of care, central laboratories, and others
Because of its widespread use in diagnostics, the reagents segment is expected to hold a dominant market share during the forecast period. Furthermore, the introduction of new products contributes to the segment's expansion. The COVID-19 application segment is expected to dominate the global infectious disease market. The segment is expected to grow at a rapid pace in the coming years as technology advances to enable automated and high-throughput testing. The central laboratories end-user segment is expected to dominate the global infectious disease market in the coming years. Because of their large market share, these laboratories have a significant presence in emerging and underdeveloped markets. According to technology, the immunoassay segment will account for a significant revenue share of the global infectious disease market's growth. The increased demand for immunoassay methods involving various types of Enzyme-Linked Immunosorbent Assay is being driven by an increase in the outbreak of infectious diseases and an increase in the need for early diagnosis (ELISA).
North America has dominated the market in the past and is expected to do so again during the forecast period. Rising epidemiology of infectious diseases in this region, as well as increased R&D activities are major factors supporting the growth of the global infectious disease market. Furthermore, rising government involvement contributes to the growth of the global infectious disease market. According to the KAISER FAMILY FOUNDATION, noncommunicable diseases (NCDs) are the leading causes of death and disability worldwide, killing more than three out of every five people and accounting for more than half of the global disease burden. Though not historically a major focus, the United States government's attention to NCDs has recently increased. U.S. involvement in global NCDs has largely consisted of health diplomacy, scientific research, and technical assistance, frequently drawing on the U.S. government's domestic experience with NCDs, as well as some funding. For example, the United States has played a critical role in international efforts to define global priorities and monitor country efforts to reduce the impact of NCDs.
In the coming years, Asia Pacific is expected to have the fastest growing CAGR. Increasing healthcare expenditure in the region is one of the driving forces behind the expansion of the global infectious disease market. Furthermore, the presence of developing economies like China and India, which have a high prevalence of infectious diseases and limited access to healthcare, is gradually increasing.
The prominent players of the global infectious disease market involve Becton Dickinson and Company, bioMérieux SA, Abbott Laboratories, Quidel Corporation, OraSure Technologies, Danaher Corporation, and among others
Market By Product
Market By Application
TB and Drug-resistant TB
Gastro-intestinal Panel Testing
Market By Technology
Market By End-User
Point of care
Market By Geography
• Rest of Europe
• South Korea
• Rest of Asia-Pacific
• Rest of Latin America
Middle East & Africa
• South Africa
• Rest of Middle East & Africa
Infectious disease market is expected to reach a market value of around US$ 24.5 Bn by 2027.
The infectious disease market is expected to grow at a CAGR of around 5.7% from 2020 to 2027.
Based on product, reagents segment is the leading segment in the overall market.
Technological advancements is one of the prominent factor that drive the demand for infectious disease market.
Becton Dickinson and Company, bioMérieux SA, Abbott Laboratories, Quidel Corporation, OraSure Technologies, Danaher Corporation, and others.
North America is anticipated to grab the highest market share in the regional market
Asia Pacific is expected to be the fastest growing market in the forthcoming years